Drug Profile
DTaP poliovirus vaccine paediatric - Sanofi
Alternative Names: DTaP-IPV - sanofi pasteur; QuadracelLatest Information Update: 04 Apr 2022
Price :
$50
*
At a glance
- Originator sanofi pasteur
- Developer Sanofi; sanofi pasteur
- Class Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 31 Jan 2017 Launched for Pertussis, Poliomyelitis, Tetanus and Diphtheria (In children) in USA (IM)
- 04 Oct 2015 No recent reports of development identified - Phase-III for Diphtheria (In children) in Puerto Rico (IM)
- 04 Oct 2015 No recent reports of development identified - Phase-III for Pertussis (In children) in Puerto Rico (IM)